Functionalization of the Chalcone Scaffold for the Discovery of Novel Lead Compounds Targeting Fungal Infections.
Animals
Antifungal Agents
/ chemistry
Biofilms
/ drug effects
Candida albicans
/ drug effects
Chalcones
/ chemistry
Chlorocebus aethiops
Dose-Response Relationship, Drug
Fungi
/ drug effects
Inhibitory Concentration 50
Lead
/ chemistry
Microbial Sensitivity Tests
Molecular Structure
Vero Cells
Virulence Factors
Yeasts
/ drug effects
Candida albicans chalcone scaffold
anti-virulence agents
biofilm
clinically relevant yeasts
fluorine atom
yeast-to-hyphae transition
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
21 Jan 2019
21 Jan 2019
Historique:
received:
28
11
2018
revised:
09
01
2019
accepted:
16
01
2019
entrez:
24
1
2019
pubmed:
24
1
2019
medline:
12
4
2019
Statut:
epublish
Résumé
The occurrence of invasive fungal infections represents a substantial threat to human health that is particularly serious in immunocompromised patients. The limited number of antifungal agents, devoid of unwanted toxic effects, has resulted in an increased demand for new drugs. Herein, the chalcone framework was functionalized to develop new antifungal agents able to interfere with cell growth and with the infection process. Thus, a small library of chalcone-based analogues was evaluated in vitro against
Identifiants
pubmed: 30669643
pii: molecules24020372
doi: 10.3390/molecules24020372
pmc: PMC6359675
pii:
doi:
Substances chimiques
Antifungal Agents
0
Chalcones
0
Virulence Factors
0
Lead
2P299V784P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Med Chem. 1999 Dec;6(12):1125-49
pubmed: 10519918
Trends Microbiol. 2003 Jun;11(6):272-9
pubmed: 12823944
J Ethnopharmacol. 2006 Jul 19;106(3):290-302
pubmed: 16698208
J Med Chem. 2008 Aug 14;51(15):4359-69
pubmed: 18570365
Nat Prod Rep. 2010 Jul;27(7):1084-98
pubmed: 20485730
Med Mycol. 2011 Apr;49(3):253-62
pubmed: 21039308
Curr Med Chem. 2011;18(5):733-66
pubmed: 21182484
Curr Med Chem. 2012;19(2):209-25
pubmed: 22320299
Clin Microbiol Infect. 2012 Jul;18(7):E246-7
pubmed: 22563750
Science. 2012 May 11;336(6082):647
pubmed: 22582229
Nat Prod Rep. 2012 Sep;29(9):1007-21
pubmed: 22786554
J Med Microbiol. 2013 Jan;62(Pt 1):10-24
pubmed: 23180477
Sci Transl Med. 2012 Dec 19;4(165):165rv13
pubmed: 23253612
Drugs. 2013 Jun;73(9):919-34
pubmed: 23729001
Future Microbiol. 2013 Oct;8(10):1325-37
pubmed: 24059922
Eur J Med Chem. 2014 May 6;78:157-66
pubmed: 24681980
BMC Complement Altern Med. 2014 Oct 23;14:409
pubmed: 25338676
Eur J Med Chem. 2015 Aug 28;101:496-524
pubmed: 26188621
Toxicology. 2015 Oct 2;336:26-33
pubmed: 26201061
Med Mycol Case Rep. 2016 Mar 08;11:21-3
pubmed: 27069848
Curr Top Med Chem. 2016;16(28):3274-3302
pubmed: 27150370
Molecules. 2016 May 16;21(5):
pubmed: 27196880
PLoS One. 2016 Jun 10;11(6):e0157188
pubmed: 27284694
Mycoses. 2017 Apr;60(4):273-279
pubmed: 28150341
Microb Pathog. 2017 Jun;107:372-379
pubmed: 28428132
J Med Chem. 1988 Dec;31(12):2235-46
pubmed: 2848124
Chem Rev. 2017 Jun 28;117(12):7762-7810
pubmed: 28488435
Lancet Infect Dis. 2017 Nov;17(11):e334-e343
pubmed: 28774701
Front Med (Lausanne). 2018 Feb 13;5:28
pubmed: 29487851
Eur J Med Chem. 2018 May 25;152:527-541
pubmed: 29758517